In addition, in the same study by Cordonnier et al., PD-1 mAbs pembrolizumab was used to treat melanoma, and it was found that the level of exosomal PD-L1 before administration was negatively correlated with the response rate to pembrolizumab therapy. Here, PDCD1 is linked to melanoma.